Gene transfer vector biodistribution: Pivotal safety studies in clinical gene therapy development

Gene Therapy

Volumn 11, Issue , 2004, Pages S98-S108

  Gonin, P ^a   Gaillard, C ^b  

^a GÉNÉTHON   (France)

^b GenoSafe SAS   (France)

Author keywords

Biodistribution; Gene transfer; Gene vectors; Quantitative PCR; Safety; Toxicology

Indexed keywords

ADENOVIRUS VECTOR; HERPESVIRUS VECTOR; NAKED DNA; PARVOVIRUS VECTOR; PLASMID DNA; PLASMID VECTOR; RETROVIRUS VECTOR;

DRUG DISTRIBUTION; DRUG SAFETY; GENE AMPLIFICATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GERM LINE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADENOVIRIDAE; ANIMALIA;

EID: 5444276384     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302378     Document Type: Review

References (80)

1. Cichon G et al. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J Gene Med 1999; 1: 360-371.
2. Bernt KM et al. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 2003; 8: 746-755.
3. Hiltunen MO et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000; 14: 2230-2236.
4. Vajanto I et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 2002; 4: 371-380.
5. Colmenero P et al. Recombinant Semliki forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response. Gene Therapy 2001; 8: 1307-1314.
6. Ohashi K, Park F, Kay MA. Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivo. Hum Gene Ther 2002; 13: 653-663.
7. Garcia-Banuelos J et al. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Therapy 2002; 9: 127-134.
8. Wood M et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999; 6: 367-372.
9. Kanerva A et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
10. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Therapy 2001; 8: 1347-1353.
11. Peng KW et al. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Therapy 2001; 8: 1456-1463.
12. Pan D et al. Biodistribution and toxicity studies of VSVG- pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther 2002; 6: 19-29.
13. Hanke T et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 2002; 21: 108-114.
14. Klein D, Bugl B, Gunzburg WH, Salmons B. Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR. Gene Therapy 2000; 7: 458-463.
15. Wildner O, Morris JC. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: dissemination, persistence, shedding, and pathogenicity. Hum Gene Ther 2002; 13: 101-112.
16. Morris-Downes MM et al. Semliki forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 2001; 19: 1978-1988.
17. Lai L et al. A preliminary evaluation of recombinant adeno- associated virus biodistribution in rhesus monkeys after intrahepatic inoculation in utero. Hum Gene Ther 2002; 13: 2027-2039.
18. Todo T et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000; 2: 588-595.
19. Oh YK et al. Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Therapy 2001; 8: 1587-1592.
20. Oh YK et al. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 2001; 19: 4519-4525.
21. Lovatt A. Applications of quantitative PCR in the biosafety and genetic stability assessment of biotechnology products. J Biotechnol 2002; 82: 279-300.
22. Verdier F, Descotes J. Preclinical safety evaluation of human gene therapy products. Toxicol Sci 1999; 47: 9-15.
23. Imboden M et al. Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Hum Gene Ther 2003; 14: 1037-1048.
24. Haworth R, Pilling AM. The PCR assay in the preclinical safety evaluation of nucleic acid medicines. Hum Exp Toxicol 2000; 19: 267-276.
25. Zinn KR et al. Imaging and tissue biodistribution of 99mTc- labeled adenovirus knob (serotype 5). Gene Therapy 1998; 5: 798-808.
26. Bogdanov Jr A, Tung CH, Bredow S, Weissleder R. DNA binding chelates for nonviral gene delivery imaging. Gene Therapy 2001; 8: 515-522.
27. Charrois GJ, Allen TM. Rate of biodistribution of STEALTH(R) liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 2003; 1609: 102-108.
28. Collard WT et al. Biodistribution, metabolism, and in vivo gene expression of low molecular weight glycopeptide polyethylene glycol peptide DNA co-condensates. J Pharm Sci 2000; 89: 499-512.
29. Cui Z, Mumper RJ. Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: in vitro and in vivo evaluation. Bioconjug Chem 2002; 13: 1319-1327.
30. Kosuga M et al. Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: involvement of cross-correction in wide-spread distribution of the gene products and longterm effects of CTLA-4Ig coexpression. Mol Ther 2000; 1: 406-413.
31. Hackett NR et al. Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol Ther 2000; 2: 649-656.
32. Senoo M et al. Adenovirus-mediated in utero gene transfer in mice and guinea pigs: tissue distribution of recombinant adenovirus determined by quantitative TaqMan-polymerase chain reaction assay. Mol Genet Metab 2000; 69: 269-276.
33. Turunen MP et al. Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther 2002; 6: 306-312.
34. Paielli DL et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication- competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 2000; 1: 263-274.
35. Lehtolainen P et al. Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo. Gene Therapy 2002; 9: 1693-1699.
36. Ponnazhagan S et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997; 190: 203-210.
37. Nathwani AC et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258-1265.
38. Watson GL et al. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Therapy 1998; 5: 1642-1649.
39. Favre D et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther 2001; 4: 559-566.
40. Song S et al. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV- SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther 2002; 6: 329-335.
41. Arruda VR et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 2001; 4: 586-592.
42. Herzog RW et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
43. Monahan PE et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Therapy 1998; 5: 40-49.
44. Chan JM et al. Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 2002; 6: 727-736.
45. Kay MA et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
46. Lew D et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995; 6: 553-564.
47. Liu Y et al. Cationic liposome-mediated intravenous gene delivery. J Biol Chem 1995; 270: 24864-24870.
48. Mahato RI, Kawabata K, Takakura Y, Hashida M. In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J Drug Target 1995; 3: 149-157.
49. Mahato RI et al. Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. J Pharm Sci 1995; 84: 1267-1271.
50. Thierry AR et al. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 1995; 92: 9742-9746.
51. Nabel EG et al. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 1992; 3: 649-656.
52. Stewart MJ et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 1992; 3: 267-275.
53. Nabel GJ et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11311.
54. Stopeck AT et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15: 341-349.
55. Thomas SM et al. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Ther 2003; 10: 518-528.
56. Koshkina NV et al. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethylene- imine complexes: optimization of pulmonary delivery and retention. Mol Ther 2003; 8: 249-254.
57. Parker SE et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999; 10: 741-758.
58. Dagnaes-Hansen F et al. Physiological effects of human growth hormone produced after hydrodynamic gene transfer of a plasmid vector containing the human ubiquitin promotor. J Mol Med 2002; 80: 665-670; Epub 2002 Sep 2024.
59. Deisboeck TS et al. Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study. Gene Therapy 2003; 10: 1225-1233.
60. Varghese S et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001; 12: 999-1010.
61. Loudon PT et al. Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients. J Gene Med 2001; 3: 458-467.
62. Indraccolo S et al. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res 2002; 62: 6099-6107.
63. MacKenzie TC et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002; 6: 349-358.
64. Behrens A et al. Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest Ophthalmol Vis Sci 2002; 43: 968-977.
65. Ye X et al. Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gene Ther 1998; 9: 2135-2142.
66. Peters AH et al. Absence of germline infection in male mice following intraventricular injection of adenovirus. Mol Ther 2001; 4: 603-613.
67. Pachori AS et al. Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem Biophys Res Commun 2004; 313: 528-533.
68. Couto L, Parker A, Gordon JW. Direct exposure of mouse spermatozoa to very high concentrations of a serotype-2 adeno- associated virus gene therapy vector fails to lead to germ cell transduction. Hum Gene Ther 2004; 15: 287-291.
69. Frederickson RM, Carter BJ, Pilaro AM. Nonclinical toxicology in support of licensure of gene therapies. Arlington, VA, USA, March 13-14, 2003. Mol Ther 2003; 8: 8-10.
70. Oualikene W, Gonin P, Eloit M. Lack of evidence of phenotypic complementation of E1A/E1B-deleted adenovirus type 5 upon superinfection by wild-type virus in the cotton rat. J Virol 1995; 69: 6518-6524.
71. Stribling R et al. Aerosol gene delivery in vivo. Proc Natl Acad Sci USA 1992; 89: 11277-11281.
72. Sene C et al. Aerosol-mediated delivery of recombinant adenovirus to the airways of nonhuman primates. Hum Gene Ther 1995; 6: 1587-1593.
73. Bellon G et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997; 8: 15-25.
74. Ramirez JC et al. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 2003; 148: 827-839.
75. Brunetti-Pierri N et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
76. Ferber D. Gene therapy. Safer and virus-free? Science 2001; 294: 1638-1642.
77. Guillaume C et al. Aerosolization of cationic lipid-DNA complexes: lipoplex characterization and optimization of aerosol delivery conditions. Biochem Biophys Res Commun 2001; 286: 464-471.
78. Eastman SJ et al. Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complexes. Hum Gene Ther 1997; 8: 313-322.
79. Sawa T et al. Intraluminal water increases expression of plasmid DNA in rat lung. Hum Gene Ther 1996; 7: 933-941.
80. Schreier H, Gagne L, Conary JT, Laurian G. Simulated lung transfection by nebulization of liposome cDNA complexes using a cascade impactor seeded with 2-CFSME0-cells. J Aerosol Med 1998; 11: 1-13.